Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Department of Physiology, Anatomy & Genetics (DPAG) have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.

Blue and white capsules pill in blister pack arranged neatly together

Hydroxychloroquine (HCQ), a drug normally used to treat malaria, has recently been touted as a potential treatment for coronavirus. International interest in the drug was raised following reports of US President Donald Trump taking the drug to ward off COVID-19 and there have been clinical trials in several countries testing its effectiveness. However, many scientists have warned about side effects of using HCQ, which has led to the World Health Organisation temporarily suspending several studies over safety fears. 

Recent reports on the use of HCQ alone, or combined with an antibiotic called azithromycin (AZM), in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have specifically raised concerns over cardiac safety. However, so far little has been known about the mechanisms behind HCQ and AZM therapy to help evaluate cardiac safety, and therefore conclusively determine if it is unsafe for the heart.

A new international study, on which the DPAG groups of Professor David Paterson, with Dr Dan Li, and Associate Professor Neil Herring have collaborated, has provided mechanistic insight into how HCQ alone and HCQ with AZM affects cardiac electrophysiology.

Read the full story on the DPAG website

Similar stories

Student Prizes for Biomedical Sciences and Medicine 2020-2021

Awards and Appointments General

Congratulations to all our Biomedical Sciences students and Medicine students who have been awarded prizes during the 2020-2021 academic year.

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Why we must expand newborn screening

General Research

Professor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.

Top place for Oxford Clinical Medical Student in prestigious national Ophthalmology Duke Elder Prize Examination

Awards and Appointments General

Sixth year Clinical Medical student, Ryan Purdy (Worcester College), placed first in the Royal College of Ophthalmology's annual Prize Examination.